Status:
COMPLETED
Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years
Lead Sponsor:
Sanofi Pasteur, a Sanofi Company
Conditions:
RSV Infection
hMPV
Eligibility:
All Genders
60-75 years
Phase:
PHASE1
Brief Summary
VAV00039 is a first-in-human (FiH) study to assess the safety and immunogenicity (in adult participants aged 60-75 years) after a single injection of different dose formulations of an RSV/hMPV vaccine...
Detailed Description
The duration of participation will be approximately 6 months for each participant.
Eligibility Criteria
Inclusion
- Aged 60 to 75 years on the day of inclusion
- A female participant is eligible to participate if she is post-menopausal for at least 1 year, or surgically sterile
Exclusion
- Any condition which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives.
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Key Trial Info
Start Date :
October 9 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 9 2025
Estimated Enrollment :
385 Patients enrolled
Trial Details
Trial ID
NCT06583031
Start Date
October 9 2024
End Date
October 9 2025
Last Update
November 20 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Site # 0361004
Botany, New South Wales, Australia, 2019
2
Site # 031001
Brookvale, New South Wales, Australia, 2100
3
Site # 0361006
Miranda, New South Wales, Australia, 2228
4
Site # 0361002
Wollongong, New South Wales, Australia, 2500